Company profile
Edesa Biotech, Inc. -
Pipeline3 assets
- EB06 Anti-CXCL10 Monoclonal antibodyEB06 / CXCL10 / Monoclonal antibody / Dermatological diseasesVitiligoPhase 2Health Canada CTA approved; IND in processCanadaUnited States
- EB01 (daniluromer)EB01 / sPLA2 / Topical sPLA2 inhibitor / Dermatological diseasesAllergic contact dermatitisPhase 2b completedTopline results available
- ParidiprubartEB05 / TLR4 / Monoclonal antibody / Respiratory diseasesAcute respiratory distress syndromePhase 3Phase 3 results reported; selected for U.S. government-funded Phase 2 platform studyUnited StatesCanada
Latest news8 items
All newsEdesa Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
Presentation / Abstract • Phase 3Oral presentation Fri, Jun 5, 2026, 4:30 PM BST
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury
Presentation / Abstract • Phase 3Oral presentation Fri, Jun 5, 2026, 4:30 PM local time
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
Presentation / Abstract • Phase 3
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
Trial Results • Phase 3